Product Review Sacubitril/Valsartan (Entresto®) Update 2020 Prof Andrew Sindone

In this review:

This publication reviews clinical trial evidence supporting use of the angiotensin receptor neprilysin
inhibitor sacubitril/valsartan (Entresto®) in patients with heart failure and reduced ejection fraction.
It presents primary outcomes and key sub-analyses of the PARADIGM-HF trial,1-6 as well the PIONEERHF trial in stabilised patients with acute decompensated heart failure,7 and the recently published EVALUATE-HF and PROVE-HF trials,8,9 which investigated the effects of sacubitril/valsartan on cardiac remodelling. Health-related quality of life and adverse event data are also reviewed. Sacubitril/valsartan was first registered by Medsafe in 2016 for the treatment of patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction.10 This review is supported by an educational grant from Novartis (NZ) Ltd.

Please login below to download this issue (PDF)

Subscribe